| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
24038 |
| Drug |
Enfortumab vedotin in combination with pembrolizumab |
| Brand |
Padcev®in combination with Keytruda® |
| Indication |
Enfortumab vedotin in combination with pembrolizumab is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy. |
| Rapid review commissioned |
23/09/2024 |
| Rapid review completed |
22/10/2024 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
30/10/2024 |
| Pre-submission consultation with Applicant |
04/12/2024 |
| Full submission received from Applicant |
13/03/2025 |
| Preliminary review sent to Applicant |
08/10/2025 |
| NCPE assessment re-commenced |
05/11/2025 |
